New drug combo aims to stop liver cancer recurrence after surgery

NCT ID NCT07324824

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether giving two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—before surgery can help prevent liver cancer from coming back. The study includes 37 adults with resectable liver cancer that is beyond the Milan criteria, meaning it is more advanced than usual surgical limits. Participants will receive the drugs for a few cycles before surgery, and researchers will track how many remain cancer-free one year later.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sintilimab and bevacizumab biosimilar (immunotherapy and targeted therapy drugs)
What this could lead to
If successful, this combination could become a standard pre-surgery treatment to lower the chance of liver cancer returning after surgery.
What could go wrong
This is a small, early-phase study with only 37 participants and no comparison group. The treatment may cause side effects, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEVACIZIMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.